A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic Gastroparesis
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs TD 8954 (Primary)
- Indications Diabetic gastroparesis; Gastroparesis
- Focus Pharmacokinetics
- Sponsors Takeda
- 05 Jan 2018 Status changed from not yet recruiting to recruiting.
- 21 Nov 2017 Planned initiation date changed from 3 Oct 2017 to 30 Nov 2017.
- 15 Sep 2017 New trial record